Mostrar el registro sencillo del ítem

dc.contributor.authorOlloquequi, Jordi
dc.contributor.authorEttcheto, Miren
dc.contributor.authorCano, Amanda
dc.contributor.authorFortuna, Ana
dc.contributor.authorBicker, Joana
dc.contributor.authorSánchez-Lopez, Elena
dc.contributor.authorPaz, Cristian
dc.contributor.authorUreña, Jesús
dc.contributor.authorVerdaguer, Ester
dc.contributor.authorAuladell, Carme
dc.contributor.authorCamins, Antoni
dc.date.accessioned2024-04-10T01:03:05Z
dc.date.available2024-04-10T01:03:05Z
dc.date.issued2023
dc.identifier10.3390/ijms241814177
dc.identifier.issn16616596
dc.identifier.urihttps://hdl.handle.net/20.500.12728/10557
dc.description.abstractLicochalcone A (Lico-A) is a flavonoid compound derived from the root of the Glycyrrhiza species, a plant commonly used in traditional Chinese medicine. While the Glycyrrhiza species has shown promise in treating various diseases such as cancer, obesity, and skin diseases due to its active compounds, the investigation of Licochalcone A’s effects on the central nervous system and its potential application in Alzheimer’s disease (AD) treatment have garnered significant interest. Studies have reported the neuroprotective effects of Lico-A, suggesting its potential as a multitarget compound. Lico-A acts as a PTP1B inhibitor, enhancing cognitive activity through the BDNF-TrkB pathway and exhibiting inhibitory effects on microglia activation, which enables mitigation of neuroinflammation. Moreover, Lico-A inhibits c-Jun N-terminal kinase 1, a key enzyme involved in tau phosphorylation, and modulates the brain insulin receptor, which plays a role in cognitive processes. Lico-A also acts as an acetylcholinesterase inhibitor, leading to increased levels of the neurotransmitter acetylcholine (Ach) in the brain. This mechanism enhances cognitive capacity in individuals with AD. Finally, Lico-A has shown the ability to reduce amyloid plaques, a hallmark of AD, and exhibits antioxidant properties by activating the nuclear factor erythroid 2-related factor 2 (Nrf2), a key regulator of antioxidant defense mechanisms. In the present review, we discuss the available findings analyzing the potential of Lico-A as a neuroprotective agent. Continued research on Lico-A holds promise for the development of novel treatments for cognitive disorders and neurodegenerative diseases, including AD. Further investigations into its multitarget action and elucidation of underlying mechanisms will contribute to our understanding of its therapeutic potential. © 2023 by the authors.es_ES
dc.description.sponsorshipFundación ADEY; Institut de Neurociències UB, (CEX2021-001159-M); Fundação para a Ciência e a Tecnologia, FCT, (127303); Generalitat de Catalunya, (2021 SGR 00288); Instituto de Salud Carlos III, ISCIII, (CD22/00125); Ministerio de Ciencia e Innovación, MICINN, (PID2021-122473OA-I00, PID2021-123462OB-I00); Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, CIBERNED, (CB06/05/2004, PI2021/03)es_ES
dc.language.isoenes_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)es_ES
dc.subjectcognitive enhancementes_ES
dc.subjectmulti-target therapyes_ES
dc.subjectneurodegenerationes_ES
dc.titleLicochalcone A: A Potential Multitarget Drug for Alzheimer’s Disease Treatmentes_ES
dc.typeArticlees_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem